Recent News

• 01.30.2026 - IO Biotech Provides Corporate Update
• 12.15.2025 - IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
• 11.26.2025 - IO Biotech Announces Participation in Upcoming December Investor Conferences
• 11.14.2025 - IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights
• 10.20.2025 - IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
• 09.29.2025 - IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Recent Filings

• 01.23.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.21.2026 - EX-99.1 EX-99.1
• 01.21.2026 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 11.21.2025 - 8-K Current report
• 11.18.2025 - EX-99.1 EX-99.1
• 11.18.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.14.2025 - 8-K Current report